{"prompt": "['Alliance A221504', 'Patients should avoid consumption of grapefruit or grapefruit juice.', 'Drug Interactions', 'Concomitant use of naloxegol is not recommended with the following classes of medications:', 'Strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole [except topical use],', 'cyclosporine, indinavir, nelfinavir, ritonavir, itraconazole, verapamil)', 'Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil)', 'Strong CYP3A4 inducers (e.g., rifampin)', 'Opioid antagonists and mixed agonists/antagonists. EXAMPLES of such medications include:', 'pentazocine, buprenorphine, nalbuphine, naloxone and other naloxone containing products such', 'as oxycodone/naloxone combinations [e.g., TarginR], naltrexone and other naltrexone', 'containing products such as morphine/naltrexone combinations [e.g., EmbedaR],', 'methylnaltrexone [RelistorR], or alvimopan [EnteregR]).', 'Pharmacokinetics', 'Absorption: rapid. With a high fat meal, Cmax and AUC increase by 30% and 45% respectively.', 'Distribution: Vd 968-2140 L.', 'Protein binding: Low at approximately 4.2%.', 'Metabolism: Primarily hepatic via CYP3A4.', 'Half-life: 6-11 hours.', 'Excretion: primarily fecal (68%, approximately 16% as unchanged drug); urinary (16%, <6%', 'as unchanged drug).', 'Adverse Events', 'Warnings/Precautions.', 'Gastrointestinal Perforation: Gastrointestinal perforation has been reported with another', 'peripherally acting opioid antagonist in patients with conditions associated with compromised', 'structural integrity of the gastrointestinal tract wall. Monitor for the development of severe,', 'persistent or worsening abdominal pain; discontinue study drug and obtain urgent medical', 'evaluation of patients who develop this symptom.', 'Opioid Withdrawal: Hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and', 'yawning have occurred in patients treated with naloxegol. Patients receiving methadone have a', 'higher frequency of gastrointestinal adverse reactions possibly related to opioid withdrawal,', 'compared to patients receiving other opioids. Patients having disruptions to the blood-brain', 'barrier may be at increased risk for opioid withdrawal or reduced analgesia. Monitor for', 'symptoms of opioid withdrawal, particularly in such patients.', 'Adverse events:', '>10%:', 'GI: Abdominal pain', '1%-10%:', 'Central Nervous System: Headache', 'Dermatologic: Hyperhidrosis', 'GI: Diarrhea, nausea, flatulence, vomiting', 'Table 1 lists adverse reactions in pooled data from clinical studies in non-cancer patients', 'receiving naloxegol for opioid-induced constipation, and occurring in > 3% of patients', 'receiving 12.5 mg or 25 mg naloxegol and at an incidence greater than placebo.', '42', 'Update 2', 'Version Date 6/25/2019']['Alliance A221504', 'Adverse reaction', 'Naloxegol 25 mg', 'Naloxegol 12.5 mg', 'Placebo', '(n = 446)', '(n = 441)', '(n = 444)', 'Abdominal pain', '21%', '12%', '7%', 'Diarrhea', '9%', '6%', '5%', 'Nausea', '8%', '7%', '5%', 'Flatulence', '6%', '3%', '3%', 'Vomiting', '5%', '3%', '4%', 'Headache', '4%', '4%', '3%', 'Hyperhidrosis', '3%', '<1%', '<1%', 'Nursing Guidelines', 'Upon starting the study, the patient and caregiver should be shown the two different', 'naloxegol/placebo bottles and different colors of pills with instructions to take one tablet from', 'each bottle daily; repeat demonstration from the patient or caretaker is recommended. Patient', 'should be reminded to take naloxegol/placebo at least one hour before a meal or at least two', 'hours afterwards. Grapefruit and grapefruit juice should be avoided while on naloxegol/placebo.', 'The patient medication diary should be explained to the patient and caregiver with instructions', 'to note time/date of administration of naloxegol/placebo each day. The level and incidence of', 'pain should be noted on the Pain and Pain Medication Diary using a scale of 0-10.', 'Patients should be instructed to call the site coordinator whenever a new drug is ordered,', 'especially if the provider is outside of the cancer center and not fully aware of the study', 'requirements and limitations. In the event of hospital admission, the study coordinator should', 'monitor any new drugs to avoid undesirable interactions.', 'Patients should be instructed to call the site coordinator with any concerns. Ideally, a 24-hour', 'number should be provided to the patient.', 'In the event that a 3-week interval visit is missed by the patient, the site coordinator can call the', 'patient and obtain responses to the questionnaire(s) items OR discuss mailing the self-reported', 'questionnaires with a stamped, returned envelope for return.', '10.2 Placebo', 'A matching placebo will be provided by Astra Zeneca. It will match the active naloxegol 12.5', 'and 25 mg tablets in size, shape and color. The placebo tablets contain mannitol,', 'microcrystalline cellulose and magnesium stearate. The coating material contains hypromellose,', 'iron oxide/ferric oxide (red, black and yellow), macrogols/polyethylene glycol and titanium', 'dioxide.', '11.0 HEALTH OUTCOMES MEASURES', 'Each questionnaire administered in this study is described below. These self-reported questionnaires', 'are expected to take less than 15 minutes for completion and be minimally burdensome. In the event', 'that the patient is unable to complete the questionnaires, the local study coordinator may help the', 'patient. Patients appreciate being asked about their symptoms on such questionnaires, and usually do', 'not find them difficult or inconvenient to fill out. 74', '11.1 FACT-L', 'The FACT-L75 includes the FACT-G [version 4.0], developed by Cella et al76 as an overall', 'cancer-specific HRQoL questionnaire, with a 9-item subscale concerning specific lung cancer', 'issues. The FACT-G consists of a self-report 28-item HRQoL measure grouped into four', 'subscales: physical well-being (PWB), social/family well-being (SFWB), emotional well-being', '43', 'Update 2', 'Version Date 6/25/2019']\n\n###\n\n", "completion": "END"}